Newsroom

VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility
Press Release
VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility
VectorBuilder has launched a major upgrade to VectorBee, its free DNA software. The enhanced version gives researchers greater control over DNA and protein sequence design while streamlining the journey from vector design to ordering. Read More ››
VectorBuilder Partners with MaxCyte<sup>®</sup> to Advance Clinical-Grade Cell Engineering
Press Release
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
VectorBuilder and MaxCyte have entered into a strategic partnership to co-develop a novel platform technology for ex vivo cell engineering. The collaboration integrates VectorBuilder’s proprietary MiniVec™ plasmid system with MaxCyte’s clinical-grade electroporation platform to advance next-generation cell therapy development. Read More ››
VectorBuilder to Invest $50 Million in Chicago Biomanufacturing and R&D Center
Press Release
VectorBuilder to Invest $50 Million in Chicago Biomanufacturing and R&D Center
VectorBuilder, a global leader in gene delivery technologies, today announced plans to invest $50 million to establish a new Advanced Biomanufacturing and R&D Center in Chicago, marking a major expansion of the company’s regional operations and long-term commitment to supporting the development of genetic medicines. Read More ››
VectorBuilder to Present on Therapeutic Vector Design at ASGCT 2026
Press Release
VectorBuilder to Present on Therapeutic Vector Design at ASGCT 2026
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11 to 15 in Boston, Massachusetts. Read More ››
VectorBuilder Secures European Patent for MiniVec™, a Plasmid Backbone Advancing Safety and Manufacturability in Genetic Medicine
Press Release
VectorBuilder Secures European Patent for MiniVec™, a Plasmid Backbone Advancing Safety and Manufacturability in Genetic Medicine
VectorBuilder today announced that its MiniVec™ plasmid system has been granted a European patent, marking a significant milestone for the company’s proprietary plasmid DNA technology and reinforcing its position at the forefront of gene delivery innovation. Read More ››
VectorBuilder to Present on Advancing AAV-Based Therapies at ARVO 2026
VectorBuilder to Present on Advancing AAV-Based Therapies at ARVO 2026
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado, from May 3 to 7. Read More ››
Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development
Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development
One of the most fundamental questions in biology is how a single fertilized egg produces the diverse cell types making up the body that bear the same genetic blueprint but distinct expression patterns. Now, a research team lead by Dr. Bruce Lahn has uncovered fundamental mechanisms driving this process. Read More ››
VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability
Press Release
VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in gene therapy development. The manuscript describing the technology is now available on bioRxiv. Read More ››
Ikarovec to advance pipeline with exclusive worldwide option to VectorBuilder’s Intravitreal Capsid Technology
Press Release
Ikarovec to advance pipeline with exclusive worldwide option to VectorBuilder’s Intravitreal Capsid Technology
Ikarovec Ltd and VectorBuilder have entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used in combination with Ikarovec’s gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD). Read More ››
VectorBuilder Redefines Plasmid Standards with MiniVec<sup>TM</sup>
Press Release
VectorBuilder Redefines Plasmid Standards with MiniVecTM
VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the MiniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now published on BioRxiv. Read More ››
VectorBuilder Wins Two IMAPAC Awards, Cementing Leadership in Gene Therapy and CDMO Innovation
Press Release
VectorBuilder Wins Two IMAPAC Awards, Cementing Leadership in Gene Therapy and CDMO Innovation
VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene Therapy Excellence Awards 2025 (APCGTEA) and the Asia-Pacific Biologics CDMO Excellence Awards 2025 (APBCEA), hosted by IMAPAC. Read More ››
VectorBuilder Honored with 2025 CDMO Leadership Award for CGT Global Category
Press Release
VectorBuilder Honored with 2025 CDMO Leadership Award for CGT Global Category
VectorBuilder, a global leader in gene delivery and technology, proudly announces that it has been awarded the "CDMO Leadership Award - Cell & Gene Therapy, Global Category" in the annual selection jointly hosted by Outsourced Pharma and Life Science Connect. The award recognizes VectorBuilder’s performance in key areas such as quality, reliability, and technical capability. Read More ››
VectorBuilder and EurekaBio Join Forces to Reduce Viral Vector Manufacturing Costs
Press Release
VectorBuilder and EurekaBio Join Forces to Reduce Viral Vector Manufacturing Costs
VectorBuilder, a global expert in gene delivery technology, and EurekaBio, a leading upstream supplier in the CGT field, are proud to announce their synergistic strategic partnership. This alliance combines EurekaBio's revolutionary EuLV™ Stable Lentiviral Production System with VectorBuilder's GMP manufacturing and regulatory support expertise, aiming to accelerate the development of life-changing therapies worldwide. Read More ››
Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials
Press Release
Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials
Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's innovative HIV vaccine into a late-stage clinical trial. Read More ››
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation
Press Release
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation
VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects. Read More ››
Please let us know what you would like to hear from us about the latest technologies or discoveries by leaving feedback or contacting us.
Design My Vector
Design My Vector
Request Design Support
Request Design Support